The STEP 8 trial was a 68-week, randomized, double-blind, double-dummy, phase 3 clinical study comparing once-weekly subcutaneous semaglutide 2.4 mg to once-daily subcutaneous liraglutide 3.0 mg in 338 adults with overweight or obesity without diabetes. Participants received lifestyle interventions alongside medication. Semaglutide led to a greater mean weight loss (−15.8%)
